Indeed, about three years after the recognition of imatinib resistance mutations in BCR-ABL-positive CML, new drugs are now in clinical trials that are potent inhibitors of imatinib-resistant BCR-ABL mutants [13,14]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.